YU67703A - Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja - Google Patents

Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja

Info

Publication number
YU67703A
YU67703A YU67703A YUP67703A YU67703A YU 67703 A YU67703 A YU 67703A YU 67703 A YU67703 A YU 67703A YU P67703 A YUP67703 A YU P67703A YU 67703 A YU67703 A YU 67703A
Authority
YU
Yugoslavia
Prior art keywords
group
preventing
movement disorders
phenyl
alkyl
Prior art date
Application number
YU67703A
Other languages
English (en)
Inventor
Carlos Plata-Salaman
Boyu Zhao
Roy Twyman
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU67703A publication Critical patent/YU67703A/sh
Publication of RS50676B publication Critical patent/RS50676B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na postupak za sprečavanje ili lečenje poremećaja kretanja koji čini davanje subjektu kome su potrebne terapeutski efikasne količine jedinjenja izabranog iz grupe koju čine formula (I) i formula (II), gde je fenil supstituisan sa X, sa jednim do pet atoma halogena izabranih iz grupe koju čine fluor, hlor, brom i jod; i R1, R2, R3, R4, R5 i R6 su nezavisno izabrani iz grupe koju čine vodonik i C1-C4 alkil; gde C1-C4 alkil je opciono supstituisan sa fenilom (gde je fenil opciono supstituisan sa supstituentima nezavisno izabranim iz grupe koju čine halogen, C1-C4 alkil, C1-C4 alkoksi, amino, nitro i cijano).[This invention is directed to a method for preventing or treating movement disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2 R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).
YUP-677/03A 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja RS50676B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (2)

Publication Number Publication Date
YU67703A true YU67703A (sh) 2006-08-17
RS50676B RS50676B (sr) 2010-06-30

Family

ID=26765643

Country Status (28)

Country Link
US (1) US6589985B2 (sh)
EP (1) EP1411917B1 (sh)
JP (1) JP2004527492A (sh)
KR (1) KR100858232B1 (sh)
CN (1) CN1262272C (sh)
AR (1) AR033426A1 (sh)
AT (1) ATE369130T1 (sh)
AU (1) AU2002247204B2 (sh)
BR (1) BR0207831A (sh)
CA (1) CA2439478C (sh)
CY (1) CY1106924T1 (sh)
CZ (1) CZ20032299A3 (sh)
DE (1) DE60221670T2 (sh)
DK (1) DK1411917T3 (sh)
ES (1) ES2291454T3 (sh)
HK (1) HK1067305A1 (sh)
HU (1) HUP0303344A3 (sh)
IL (2) IL157592A0 (sh)
MX (1) MXPA03007719A (sh)
MY (1) MY157373A (sh)
NO (1) NO20033803L (sh)
NZ (1) NZ551954A (sh)
PL (1) PL364679A1 (sh)
PT (1) PT1411917E (sh)
RS (1) RS50676B (sh)
RU (1) RU2294739C2 (sh)
TW (1) TWI331524B (sh)
WO (1) WO2002067926A1 (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74195C2 (uk) * 2000-07-21 2005-11-15 Орто-Макнейл Фармацевтикал, Інк. Застосування карбаматної сполуки, призначеної для попередження або лікування невропатичного болю та, асоційованих з головним болем, кластерного болю і мігрені
RU2300373C2 (ru) * 2001-02-27 2007-06-10 Орто-Макнейл Фармасьютикал, Инк. Карбаматы для предотвращения или лечения нейродегенеративных нарушений
RS50948B (sr) 2001-07-16 2010-08-31 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
KR101199499B1 (ko) * 2005-07-26 2012-11-09 얀센 파마슈티카 엔.브이. 물질 관련 장애를 치료하는 방법
EP2089011A1 (en) * 2006-10-31 2009-08-19 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101717872B1 (ko) * 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
JP6096329B2 (ja) 2013-03-12 2017-03-15 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物及び記憶損失−関連疾患の予防又は治療用組成物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3046300A1 (en) * 2016-12-14 2018-06-21 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
US10959976B2 (en) 2017-06-02 2021-03-30 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
AU2002247204B2 (en) 2006-08-24
KR20030074847A (ko) 2003-09-19
HUP0303344A2 (hu) 2004-01-28
ES2291454T3 (es) 2008-03-01
MY157373A (en) 2016-06-15
WO2002067926A1 (en) 2002-09-06
KR100858232B1 (ko) 2008-09-12
HUP0303344A3 (en) 2012-07-30
PT1411917E (pt) 2007-09-17
JP2004527492A (ja) 2004-09-09
EP1411917A1 (en) 2004-04-28
IL157592A0 (en) 2004-03-28
CA2439478C (en) 2010-05-18
RU2003128985A (ru) 2005-03-10
RU2294739C2 (ru) 2007-03-10
NO20033803D0 (no) 2003-08-26
CN1505508A (zh) 2004-06-16
DE60221670T2 (de) 2008-04-30
HK1067305A1 (en) 2005-04-08
ATE369130T1 (de) 2007-08-15
CY1106924T1 (el) 2012-09-26
IL157592A (en) 2009-12-24
NO20033803L (no) 2003-10-10
PL364679A1 (en) 2004-12-13
EP1411917B1 (en) 2007-08-08
RS50676B (sr) 2010-06-30
NZ551954A (en) 2008-07-31
BR0207831A (pt) 2004-06-22
US6589985B2 (en) 2003-07-08
CZ20032299A3 (cs) 2004-08-18
US20020151585A1 (en) 2002-10-17
TWI331524B (en) 2010-10-11
DE60221670D1 (de) 2007-09-20
CN1262272C (zh) 2006-07-05
AR033426A1 (es) 2003-12-17
CA2439478A1 (en) 2002-09-06
MXPA03007719A (es) 2004-11-12
DK1411917T3 (da) 2007-09-24

Similar Documents

Publication Publication Date Title
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
RS67603A (en) Carbamate compounds for use in the treatment of pain
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
HK1062270A1 (en) Carbamate compounds for use in preventing or treating anxiety disorders
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
IL159847A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
MY136347A (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain